Big brother, big business

| | Cardiovascular Business | Patient Care

Marketing intelligence firms that serve pharmaceutical companies apply sophisticated networking and data analytics to inform their clients about the prescribing habits of physicians as well as patient behavior. “Doctors tend not to be aware of the depths to which they are being analyzed and studied by people trying to sell them drugs and other medical products,” Jerry Avorn, MD, chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston, said in a New York Times article.

Pills tracked from doctor to patient to aid drug marketing

Related Content

Detecting coronary inflammation on CT imaging could reshape preventive cardiology
Know your options: What cardiologists recommend when alternative access is required for TAVR
New drug therapies targeting Lp(a) could be a breakthrough in cardiovascular care
Getinge ending production of cardiopulmonary surgical perfusion systems
ACC offers practical approaches for arrhythmia monitoring after stroke
FDA and Boston Scientific issue urgent alert about pacemaker failures following 2 deaths

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.